边缘的RAF——BRAF抑制剂的悖论 - Suppr

Suppr

超能文献

RAF around the edges--the paradox of BRAF inhibitors.

作者信息

Weeraratna Ashani T

出版信息

N Engl J Med. 2012 Jan 19;366(3):271-3. doi: 10.1056/NEJMe1111636.

DOI:10.1056/NEJMe1111636

PMID:22256810

Abstract

摘要

相似文献

RAF around the edges--the paradox of BRAF inhibitors.

N Engl J Med. 2012 Jan 19;366(3):271-3. doi: 10.1056/NEJMe1111636.

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

N Engl J Med. 2012 Jan 19;366(3):207-15. doi: 10.1056/NEJMoa1105358.

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.

J Clin Oncol. 2012 Jan 20;30(3):316-21. doi: 10.1200/JCO.2011.36.7680. Epub 2011 Nov 7.

[Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].

Ann Pathol. 2013 Dec;33(6):375-85. doi: 10.1016/j.annpat.2013.09.003. Epub 2013 Oct 31.

Colorectal cancer: Targeting BRAF mutations equally?

Nat Rev Clin Oncol. 2016 Jan;13(1):4. doi: 10.1038/nrclinonc.2015.190. Epub 2015 Nov 10.

Hitting the Target in BRAF-Mutant Colorectal Cancer.

J Clin Oncol. 2015 Dec 1;33(34):3990-2. doi: 10.1200/JCO.2015.63.7793. Epub 2015 Oct 12.

Paradoxical oncogenesis: are all BRAF inhibitors equal?

Pigment Cell Melanoma Res. 2013 Sep;26(5):611-5. doi: 10.1111/pcmr.12132. Epub 2013 Jul 19.

Overcoming metastatic melanoma with BRAF inhibitors.

Arch Pharm Res. 2011 May;34(5):699-701. doi: 10.1007/s12272-011-0521-5.

Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.

Clin Pharmacol Ther. 2014 Jan;95(1):24-31. doi: 10.1038/clpt.2013.197. Epub 2013 Sep 30.

Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.

J Drugs Dermatol. 2015 May;14(5):509-10.

引用本文的文献

Pseudoangiosarcoma and cutaneous collagenous vasculopathy in a patient on a Bruton's tyrosine kinase inhibitor.

JAAD Case Rep. 2024 Jul 1;51:17-21. doi: 10.1016/j.jdcr.2024.06.011. eCollection 2024 Sep.

Assessment of Retinal Pigment Epithelium Alterations and Chorioretinal Vascular Network Analyses in Patients under Treatment with BRAF/MEK Inhibitor for Different Malignancies: A Pilot Study.

J Clin Med. 2023 Feb 3;12(3):1214. doi: 10.3390/jcm12031214.

Novel insights into the pathogenesis and treatment of NRAS mutant melanoma.

Expert Rev Precis Med Drug Dev. 2021;6(4):281-294. doi: 10.1080/23808993.2021.1938545. Epub 2021 Aug 11.

A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated Mutant Melanoma (TraMel-WT).

Cancers (Basel). 2021 Apr 22;13(9):2010. doi: 10.3390/cancers13092010.

Adult pilocytic astrocytoma in the molecular era: a comprehensive review.

CNS Oncol. 2021 Mar 1;10(1):CNS68. doi: 10.2217/cns-2020-0027. Epub 2021 Jan 15.

Activation by substoichiometric inhibition.

Proc Natl Acad Sci U S A. 2020 Jan 21;117(3):1414-1418. doi: 10.1073/pnas.1918721117. Epub 2020 Jan 6.

Complete regression of primary melanoma associated with nevi involution under BRAF inhibitors: A case report and review of the literature.

Oncol Lett. 2019 May;17(5):4176-4182. doi: 10.3892/ol.2018.9738. Epub 2018 Nov 19.

Mps1 is associated with the BRAF mutation but does not rely on the classic RAS/RAF/MEK/ERK signaling pathway in thyroid carcinoma.

Oncol Lett. 2018 Jun;15(6):9978-9986. doi: 10.3892/ol.2018.8561. Epub 2018 Apr 24.

Cutaneous toxicities of new treatments for melanoma.

Clin Transl Oncol. 2018 Nov;20(11):1373-1384. doi: 10.1007/s12094-018-1891-7. Epub 2018 May 24.

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation.

Oncogenesis. 2017 May 15;6(5):e337. doi: 10.1038/oncsis.2017.36.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验